Company intelligence / Profile preview
Kalbio Global Medika
- Ownership
- Private
- Employees
- ~291
- Development stage
- Commercial
Overview
KGM has achieved commercial approval for at least one biosimilar/novel biologic in Indonesia and provides contract manufacturing services for preclinical to commercial supply. The company’s pipeline includes several biosimilars and novel biologics, with a focus on markets outside the US, Canada, Western Europe, and China. It was the first organization in Indonesia approved for production of commercial biotherapeutics.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Monoclonal antibodyProteinRecombinant proteinBiologic
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Kalbio Global Medika.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kalbio Global Medika.